Clinical Trial: FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06393816) titled 'FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum' on April 17.

Brief Summary: The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review

Study Type: Interventional

Condition: Large Cell Neuroendocrine Carcinoma of the Lung

Intervention: Drug: Durvalumab with etoposide and Carboplatin/Cisplatin

Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Trea...